Provider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment.

IF 4.3 4区医学 Q1 OBSTETRICS & GYNECOLOGY

Obstetrical & Gynecological Survey Pub Date : 2024-10-01 DOI:10.1097/OGX.0000000000001324

Ashley A Cirillo, Stephanie L Gaw

{"title":"Provider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment.","authors":"Ashley A Cirillo, Stephanie L Gaw","doi":"10.1097/OGX.0000000000001324","DOIUrl":null,"url":null,"abstract":"Importance: In 2023, the Food and Drug Administration approved 2 new products to reduce the risk of lower respiratory infections caused by respiratory syncytial virus (RSV) in infants: Beyfortus (nirsevimab; AstraZeneca/Sanofi), a single-dose monoclonal antibody for infant administration, and Abrysvo (bivalent RSVpreF vaccine; Pfizer), a single-dose maternal vaccination.Objectives: We aimed to synthesize data from the literature and the leading professional organizations to provide guidance on RSV and strategies to reduce the risk of infant infection. This information will assist prenatal care clinicians in counseling their patients regarding the choice between maternal vaccination and the infant monoclonal antibody.Evidence acquisition: A descriptive review of the guidelines from the Centers for Disease Control and Prevention, American College of Obstetrics and Gynecology (ACOG), American Academy of Pediatrics, Society for Maternal-Fetal Medicine, and the American Academy of Family Physicians.Results: All 5 organizations recommend that RSV vaccination should be offered to all pregnant people during the RSV season (September-January in the continental United States). Infants younger than 8 months entering into their first RSV season born to those who did not receive maternal vaccination or received vaccination less than 14 days prior to birth should be offered monoclonal antibody administration.Conclusions: RSV vaccination and monoclonal antibodies have the potential to significantly reduce the burden of lower respiratory tract infections due to RSV in infants. Future studies should further evaluate the durability of protection and other strategies to further protect the infant, including cocooning and the role of breast milk in immunity.","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrical & Gynecological Survey","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/OGX.0000000000001324","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Importance: In 2023, the Food and Drug Administration approved 2 new products to reduce the risk of lower respiratory infections caused by respiratory syncytial virus (RSV) in infants: Beyfortus (nirsevimab; AstraZeneca/Sanofi), a single-dose monoclonal antibody for infant administration, and Abrysvo (bivalent RSVpreF vaccine; Pfizer), a single-dose maternal vaccination.

Objectives: We aimed to synthesize data from the literature and the leading professional organizations to provide guidance on RSV and strategies to reduce the risk of infant infection. This information will assist prenatal care clinicians in counseling their patients regarding the choice between maternal vaccination and the infant monoclonal antibody.

Evidence acquisition: A descriptive review of the guidelines from the Centers for Disease Control and Prevention, American College of Obstetrics and Gynecology (ACOG), American Academy of Pediatrics, Society for Maternal-Fetal Medicine, and the American Academy of Family Physicians.

Results: All 5 organizations recommend that RSV vaccination should be offered to all pregnant people during the RSV season (September-January in the continental United States). Infants younger than 8 months entering into their first RSV season born to those who did not receive maternal vaccination or received vaccination less than 14 days prior to birth should be offered monoclonal antibody administration.

Conclusions: RSV vaccination and monoclonal antibodies have the potential to significantly reduce the burden of lower respiratory tract infections due to RSV in infants. Future studies should further evaluate the durability of protection and other strategies to further protect the infant, including cocooning and the role of breast milk in immunity.

查看原文本刊更多论文

预防婴儿呼吸道合胞病毒的医疗指南：母亲接种疫苗与婴儿单克隆抗体治疗。

重要性：2023 年，美国食品和药物管理局批准了两种新产品，以降低婴儿因呼吸道合胞病毒 (RSV) 引起下呼吸道感染的风险：Beyfortus（nirsevimab；阿斯利康/赛诺菲）是一种单剂量婴儿单克隆抗体，Abrysvo（二价 RSVpreF 疫苗；辉瑞）是一种单剂量孕产妇疫苗：我们旨在综合文献和主要专业组织的数据，为 RSV 和降低婴儿感染风险的策略提供指导。这些信息将有助于产前护理临床医生就产妇接种疫苗和婴儿单克隆抗体之间的选择为患者提供咨询：对美国疾病控制和预防中心、美国妇产科学会 (ACOG)、美国儿科学会、母胎医学会和美国家庭医生学会的指南进行了描述性回顾：所有这 5 个组织都建议在 RSV 流行季节（美国大陆的 9 月至 1 月）为所有孕妇接种 RSV 疫苗。未接种母体疫苗或出生前接种疫苗不足 14 天的孕妇所生的小于 8 个月的婴儿在进入第一个 RSV 流行季时应接种单克隆抗体：RSV疫苗接种和单克隆抗体有可能显著减少婴儿因RSV引起的下呼吸道感染。未来的研究应进一步评估保护的持久性和进一步保护婴儿的其他策略，包括茧房和母乳在免疫中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obstetrical & Gynecological Survey 医学-妇产科学

CiteScore

2.70

自引率

3.20%

发文量

245

审稿时长

>12 weeks

期刊介绍： Each monthly issue of Obstetrical & Gynecological Survey presents summaries of the most timely and clinically relevant research being published worldwide. These concise, easy-to-read summaries provide expert insight into how to apply the latest research to patient care. The accompanying editorial commentary puts the studies into perspective and supplies authoritative guidance. The result is a valuable, time-saving resource for busy clinicians.